Verrica's VP-315 Shows Potential Abscopal Effects in Basal Cell Carcinoma Phase 2 Data

Event summary

  • Verrica Pharmaceuticals to present Phase 2 data on VP-315 at the 2026 SID Annual Meeting, highlighting potential abscopal effects in basal cell carcinoma (BCC).
  • Study observed 67% reduction in untreated non-target lesions (NTLs), with 21% showing complete histologic clearance.
  • VP-315 demonstrated immune activation in remote NTLs, suggesting broader tumor microenvironment effects.
  • Presentation scheduled for May 15, 2026, during the SID Annual Meeting in Chicago.

The big picture

Verrica's VP-315 represents a novel approach to treating basal cell carcinoma, leveraging oncolytic peptide immunotherapy to potentially address the unmet need for non-surgical options. The observed abscopal effects, if confirmed, could position VP-315 as a differentiated therapy in the dermatology oncology space, particularly for patients with multiple or difficult-to-detect lesions. The data presentation at the SID Annual Meeting will be a key milestone in assessing the clinical and commercial potential of this asset.

What we're watching

Clinical Validation
Whether VP-315's observed abscopal effects can be replicated and validated in further pivotal testing.
Market Differentiation
How Verrica positions VP-315 against existing surgical and non-surgical BCC treatments.
Regulatory Pathway
The pace at which Verrica advances VP-315 through regulatory approvals for BCC and other non-melanoma skin cancers.